Kerr et al., 2012
# FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026 In April 2026, the FDA announced it would remove 12 popular peptides from Category 2 restrictions including some of the most widely used compounds in biohacking, regenerative medicine, and peptide therapy circles
Developing predictive biomarkers improves patient selection
4n, Table 2)
doi.org/10.1111/srt.12228 Russell, M., Sandhu, M., Vail, M., Haran, C., Batool, U., Leo, J
Researchers comparing GHRH-family compounds often cross-reference approved or clinically advanced analogs to understand what a successful regulatory path looks like